The Avoca Group Selects Strategic Partner, Sitrof Technologies
Sitrof Technologies
, a provider of IT and document management solutions for the life sciences industry, and
The Avoca Group
, a consulting and research organization specializing in clinical outsourcing and alliance management, today announced a strategic partnership specifically tailored for the life sciences industry.
“The Avoca Group provides comprehensive alliance and relationship management consulting services to the life sciences industry and we are always in search of best-of-breed solutions,” said Avoca President Patricia Leuchten. “By partnering with Sitrof Technologies our clients and Avoca Quality Consortium member companies will benefit as we streamline our processes through the application of the latest technologies available. In addition, as part of the partnership, Avoca and Sitrof will proactively identify ways that technology enablers can support Avoca's mission to help their clients build, measure and manage business relationships in the life sciences area."
Sitrof Technologies’ award-winning solutions have been deployed in dozens of life sciences companies including CROs, IRBs and other life sciences service partners in clinical trials, quality management and regulatory affairs. Founding partners Dan Wheeler and Bryan Reynolds have built a highly successful IT services business helping life sciences companies streamline and automate their processes.
“Unstructured content generation and the need for outsourcing are both growing at tremendous rates within life sciences companies, with no slow down in sight,” said Reynolds. “By working with The Avoca Group and Sitrof Technologies, life sciences companies can be assuredthey are implementing best practices in relationship management and qualitymanagement based on the most up-to-date, validated technologies and Business Process Management (BPM) platforms.”
Related Links:
The Avoca Group Announces Consortium on Quality Management and Oversight
Gilead Shares Final Data from Phase III MYR301 Trial of Bulevirtide in Chronic Hepatitis Delta Virus
May 7th 2025Long-term results from the study show 90% of patients with chronic HDV who achieved undetectable HDV RNA at 96 weeks of treatment remained undetectable for nearly 2 years post-treatment.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
